Jagsonpal Pharmaceuticals Reports 23% YoY Revenue Surge in Q1FY26, Net Profit Doubles

Jagsonpal Pharmaceuticals Limited, a leading pharmaceutical company, announced its unaudited financial results for the quarter ended June 30, 2025. The company reported a 23.1% YoY surge in revenue to Rs. 3756 Mn, powered by sustained performance across its key brands. Gross margins improved by 80 bps to 64.4%, backed by strong brand equity and disciplined cost management. Operating EBITDA grew 24.1% to Rs. 157 Mn, with margins at 20.8%. Net profit doubled to Rs. 108 Mn, with PAT margin expanding by 560 bps to 14.3%. The company's cash position stood at Rs. 1,609 Mn as of June 30, 2025. Jagsonpal Pharmaceuticals expects the growth momentum to continue as it deepens its presence in the domestic pharmaceutical market and looks for a strategically suitable inorganic opportunity.